Prevail Therapeutics Inc

(NASDAQ:PRVL)

Latest On Prevail Therapeutics Inc (PRVL):

Date/Time Type Description Signal Details
2021-01-25 21:16 ESTNewsEli Lilly shares up as it completes Prevail Therapeutics dealN/A
2021-01-21 13:25 ESTNewsPrevail Therapeutics Shareholders Are Getting A Big Contingent Value RightN/A
2020-12-16 12:52 ESTAnalyst RatingThe Analyst Target Price has increased from $22.63 to $23.63.Buy
2020-12-16 10:47 ESTNewsEli Lilly set to outperform on catalysts and growth prospects: Goldman SachsN/A
2020-12-15 17:09 ESTNewsPrevail Therapeutics rockets 85% on being acquired by Lilly for ~$1.04BN/A
2020-12-11 10:41 ESTNewsDosing underway in Prevail Therapeutics' gene therapy study for a type of dementiaN/A
2020-12-02 01:56 ESTNewsPrevail's gene therapy Orphan drug in Europe for a type of dementiaN/A
2020-11-26 21:17 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 01:19 ESTNewsPrevail Therapeutics nabs U.S. patent for gene therapy programN/A
2020-11-17 05:09 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:09 ESTEarnings EstimateAn EPS average of -$0.64 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-14 09:54 ESTNewsPrevail Therapeutics EPS beats by $0.09N/A
2020-11-08 00:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:53 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 00:37 ESTNewsPrevail Therapeutics' gene therapy fast track'd in U.S. neurological form of Gaucher diseaseN/A
2020-10-09 07:24 ESTNewsCitadel Advisors reports 7.0% stake in Prevail TherapeuticsN/A
2020-09-26 13:48 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:54 ESTFinancialsCompany financials have been released.Neutral
2020-09-14 18:38 ESTNewsPrevail Therapeutics Inc. (PRVL) Investor Presentation - SlideshowN/A
2020-09-11 05:22 ESTAnalyst RatingThe Analyst Target Price has increased from $22.14 to $22.63.Buy
2020-08-14 09:53 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 17:37 ESTFinancialsCompany financials have been released.Neutral
2020-08-11 21:50 ESTNewsPrevail Therapeutics EPS misses by $0.09N/A
2020-08-11 21:50 ESTNewsPrevail Therapeutics Inc. 2020 Q2 - Results - Earnings Call PresentationN/A
2020-08-11 21:49 ESTNewsPrevail Therapeutics Inc.'s (PRVL) CEO Asa Abeliovich on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-06 21:40 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:39 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:34 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:34 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 03:52 ESTNewsPrevail Therapeutics issued new U.S. patent covering PR006N/A
2020-07-27 13:31 ESTFinancialsCompany financials have been released.Neutral
2020-07-25 10:42 ESTNewsStocks To Watch: Big Focus On Big TechN/A
2020-07-23 18:11 ESTFinancialsCompany financials have been released.Neutral
2020-07-20 17:35 ESTAnalyst RatingThe Analyst Target Price has increased from $22 to $22.14.Buy
2020-07-09 09:45 ESTFinancialsCompany financials have been released.Neutral
2020-07-08 01:30 ESTAnalyst RatingThe Analyst Target Price has increased from $21.5 to $22.Buy
2020-07-01 17:32 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 13:25 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 05:27 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 05:50 ESTFinancialsCompany financials have been released.Neutral
2020-06-02 17:41 ESTEarnings EstimateAn EPS average of -$0.60 is estimated for the quarter ending on September 30, 2020.Sell
2020-06-02 17:41 ESTAnalyst RatingThe Analyst Target Price has increased from $21.33 to $21.5.Buy
2020-05-27 05:58 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 01:34 ESTFinancialsCompany financials have been released.Neutral
2020-05-20 13:35 ESTFinancialsCompany financials have been released.Neutral
2020-05-16 06:47 ESTNewsPrevail Therapeutics EPS misses by $0.06N/A
2020-05-06 06:05 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 05:33 ESTFinancialsCompany financials have been released.Neutral
2020-04-12 09:29 ESTNewsStifel likes Alector and Denali in premarket analyst actionN/A
2020-04-12 09:18 ESTNewsPrevail on go with study of gene therapy for type of dementia; shares up 7%N/A

About Prevail Therapeutics Inc (PRVL):

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

PRVL Quotes by TradingView

See Advanced Chart

General

  • Name Prevail Therapeutics Inc
  • Symbol PRVL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 66
  • Fiscal Year EndDecember
  • IPO Date2019-06-20
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.prevailtherapeutics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 7
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.71
  • Return on Assets -29%
  • Return on Equity -52%
  • Earnings Per Share -$7.80
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 787.7 million
  • EBITDA -38527688
  • Analyst Target Price $23.63
  • Book Value Per Share $5.34
View More

Share Statistics

  • Shares Outstanding 34.25 million
  • Shares Float 11.16 million
  • % Held by Insiders 1300%
  • % Held by Institutions 92.42%
  • Shares Short 1.01 million
  • Shares Short Prior Month 1.1 million
  • Short Ratio 1.3
  • Short % of Float 6%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • 52 Week High $23.35
  • 52 Week Low $9.21
  • 50 Day Moving Average 23.03
  • 200 Day Moving Average 13.95
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Prevail Therapeutics Inc (PRVL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Prevail Therapeutics Inc (PRVL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.55-$0.6514.83%
2020-06-302020-08-11$N/A-$0.66-$0.57-16.55%
2020-03-312020-05-14$N/A-$0.56-$0.48-15.51%
2019-12-312020-03-26$N/A-$0.54-$0.6314.38%
2019-09-302019-11-12$N/A-$0.62-$0.48-28.28%
2019-06-302019-08-14$N/A-$0.58-$0.54-7.41%

Prevail Therapeutics Inc (PRVL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development 12.32 million N/A 11.42 million 11.6 million 16.84 million
Income Before Tax -18.59 million N/A -18.58 million -17.84 million -20.3 million
Selling General Administrative 6.3 million N/A 7.86 million 6.96 million 4.45 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -18.5 million N/A -19.17 million -18.55 million -21.29 million
Operating Income -18.62 million N/A -19.28 million -18.55 million -21.29 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A 210000 710000 989000
Net Income From Continuing Operations -18.59 million N/A -18.58 million -17.84 million -20.3 million
Net Income Applicable to Common Shares N/A -22.1 million N/A -17.84 million -20.3 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -12.72 million -20.22 million -287000 N/A N/A
Change to Liabilities N/A -1.96 million N/A 210000 2.95 million
Total Cash Flow from Investing Activities N/A -20.22 million N/A -86000 -512000
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 30000 46000 62000 -138000 -8000
Change to Operating Activities N/A 3.34 million N/A -163000 -2.56 million
Change in Cash -29.33 million -38.52 million -18.47 million -15.02 million -19.02 million
Total Cash from Operating Activities -16.65 million -18.34 million -18.25 million -14.8 million -18.5 million
Depreciation 122000 114000 111000 64000 108000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A -173000 -21000
Change to Net Income N/A 2.26 million N/A 2.93 million 1.3 million
Capital Expenditures 170000 87000 287000 86000 512000
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities 21.54 million N/A 20.34 million 21.76 million 21.4 million
Total Stockholder Equity 112.58 million N/A 148.46 million 165.34 million 182.03 million
Other Current Liabilities N/A N/A 249000 524000 99000
Total Assets N/A N/A 168.8 million 187.1 million 203.43 million
Common Stock N/A 3000 N/A 3000 3000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings N/A -124.78 million -102.68 million -84.1 million -66.26 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A 2.82 million N/A 91000 91000
Cash 81.73 million N/A 149.58 million 168.05 million 183.07 million
Total Current Liabilities 12.75 million N/A 10.79 million 11.83 million 11.18 million
Other Stockholder Equity N/A -1000 N/A N/A N/A
Property, Plant & Equipment N/A 12.05 million N/A 12.55 million 12.84 million
Total Current Assets 96.33 million N/A 154.49 million 174.46 million 190.5 million
Long Term Investments 22.86 million N/A N/A N/A N/A
Net Tangible Assets N/A 128.66 million N/A 165.34 million 182.03 million
Short Term Investments 9.76 million N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 2.6 million N/A 3.94 million 5.16 million 4.95 million

Prevail Therapeutics Inc (PRVL) Chart:

Prevail Therapeutics Inc (PRVL) News:

Below you will find a list of latest news for Prevail Therapeutics Inc (PRVL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Prevail Therapeutics Inc (PRVL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Prevail Therapeutics Inc (PRVL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1714798/000119312520185248/0001193125-20-185248-index.htm
2019-04-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1714798/000000000019007509/0000000000-19-007509-index.htm
2019-05-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1714798/000000000019008851/0000000000-19-008851-index.htm
2019-06-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1714798/000000000019009397/0000000000-19-009397-index.htm
2020-07-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1714798/000000000020006043/0000000000-20-006043-index.htm
2019-06-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1714798/000093583619000360/0000935836-19-000360-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1714798/000093583620000149/0000935836-20-000149-index.htm
2019-06-27SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1714798/000094787119000475/0000947871-19-000475-index.htm
2019-03-27DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1714798/000095012319002856/0000950123-19-002856-index.htm
2019-05-08DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1714798/000095012319004004/0000950123-19-004004-index.htm
2019-05-07DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1714798/000095012319004005/0000950123-19-004005-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1714798/000110465920021902/0001104659-20-021902-index.htm
2020-10-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1714798/000110465920113414/0001104659-20-113414-index.htm
2019-05-24S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1714798/000119312519157078/0001193125-19-157078-index.htm
2019-05-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1714798/000119312519157094/0001193125-19-157094-index.htm
2019-05-29CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1714798/000119312519159979/0001193125-19-159979-index.htm
2019-06-10S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1714798/000119312519168749/0001193125-19-168749-index.htm
2019-06-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1714798/000119312519168761/0001193125-19-168761-index.htm
2019-06-138-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1714798/000119312519172517/0001193125-19-172517-index.htm
2019-06-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1714798/000119312519174780/0001193125-19-174780-index.htm
2019-06-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1714798/000119312519174791/0001193125-19-174791-index.htm
2019-06-19FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1714798/000119312519176016/0001193125-19-176016-index.htm
2019-06-20424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1714798/000119312519177602/0001193125-19-177602-index.htm
2019-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1714798/000119312519180270/0001193125-19-180270-index.htm
2019-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312519181337/0001193125-19-181337-index.htm
2019-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312519222603/0001193125-19-222603-index.htm
2019-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312519242120/0001193125-19-242120-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312519264057/0001193125-19-264057-index.htm
2019-11-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312519294797/0001193125-19-294797-index.htm
2019-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312519323101/0001193125-19-323101-index.htm
2020-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312520004748/0001193125-20-004748-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312520006007/0001193125-20-006007-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1714798/000119312520035624/0001193125-20-035624-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1714798/000119312520035774/0001193125-20-035774-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312520059726/0001193125-20-059726-index.htm
2020-03-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1714798/000119312520087079/0001193125-20-087079-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1714798/000119312520121009/0001193125-20-121009-index.htm
2020-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1714798/000119312520121018/0001193125-20-121018-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312520171460/0001193125-20-171460-index.htm
2020-07-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1714798/000119312520185248/0001193125-20-185248-index.htm
2020-07-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1714798/000119312520188026/0001193125-20-188026-index.htm
2020-08-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1714798/000119312520215724/0001193125-20-215724-index.htm
2020-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312520243118/0001193125-20-243118-index.htm
2020-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000119312520283331/0001193125-20-283331-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038115/0001209191-19-038115-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038117/0001209191-19-038117-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038119/0001209191-19-038119-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038121/0001209191-19-038121-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038122/0001209191-19-038122-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038123/0001209191-19-038123-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038124/0001209191-19-038124-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038127/0001209191-19-038127-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038129/0001209191-19-038129-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038130/0001209191-19-038130-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038131/0001209191-19-038131-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119038133/0001209191-19-038133-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119039015/0001209191-19-039015-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119039126/0001209191-19-039126-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119039127/0001209191-19-039127-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119039130/0001209191-19-039130-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119056998/0001209191-19-056998-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919119057001/0001209191-19-057001-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120018117/0001209191-20-018117-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120018118/0001209191-20-018118-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120018121/0001209191-20-018121-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120018123/0001209191-20-018123-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120018129/0001209191-20-018129-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120018133/0001209191-20-018133-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120018137/0001209191-20-018137-index.htm
2020-06-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120034218/0001209191-20-034218-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120034219/0001209191-20-034219-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120038055/0001209191-20-038055-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120038056/0001209191-20-038056-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120038057/0001209191-20-038057-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120038058/0001209191-20-038058-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120038059/0001209191-20-038059-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120038060/0001209191-20-038060-index.htm
2020-09-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120050090/0001209191-20-050090-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000120919120050091/0001209191-20-050091-index.htm
2019-06-13CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1714798/000135445719000310/0001354457-19-000310-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000156459019031956/0001564590-19-031956-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1714798/000156459019031957/0001564590-19-031957-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000156459019042617/0001564590-19-042617-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1714798/000156459019042732/0001564590-19-042732-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000156459020012979/0001564590-20-012979-index.htm
2020-03-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1714798/000156459020012986/0001564590-20-012986-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000156459020025266/0001564590-20-025266-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1714798/000156459020025274/0001564590-20-025274-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1714798/000156459020039112/0001564590-20-039112-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1714798/000156459020039115/0001564590-20-039115-index.htm
2018-03-14DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1714798/000171479818000002/0001714798-18-000002-index.htm
2019-06-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1714798/999999999519001379/9999999995-19-001379-index.htm
2020-07-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1714798/999999999520001719/9999999995-20-001719-index.htm
2019-05-14SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1714798/999999999719004397/9999999997-19-004397-index.htm
2019-06-18SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1714798/999999999719005627/9999999997-19-005627-index.htm

Prevail Therapeutics Inc (PRVL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Prevail Therapeutics Inc (PRVL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1300%
Institutional Ownership: 9242%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-12-24Emily MinkowChief Business OfficerBuy13,000.000.182,340.0013,000.00https://www.sec.gov/Archives/edgar/data/1714798/000120919120018117/0001209191-20-018117-index.htm
2019-06-24CARL L GORDONDirectorBuy882,352.0017.0014,999,984.0013,822,463.00https://www.sec.gov/Archives/edgar/data/1714798/000120919119039127/0001209191-19-039127-index.htm
2019-06-24ORBIMED ADVISORS LLCDirectorBuy882,352.0017.0014,999,984.0013,822,463.00https://www.sec.gov/Archives/edgar/data/1714798/000120919119039126/0001209191-19-039126-index.htm
2019-06-24Peter A. ThompsonDirectorBuy882,352.0017.0014,999,984.0013,822,463.00https://www.sec.gov/Archives/edgar/data/1714798/000120919119039130/0001209191-19-039130-index.htm